Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Trial of Anti-Angiotensin II Vaccine CYT006-AngQb in Mild to Moderate Essential Hypertension
2007-005843-93Phase 2Completed
- Sponsor
- Cytos Biotechnology AG
- Start
- Nov 2007
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in essential hypertension comparing CYT006-AngQb vaccine arm with Placebo arm (2 arms). Primary endpoints: Safety and tolerability of CYT006-AngQb, Pharmacodynamic effects and 1 more. Started Nov 2007; status: completed.
02
Drugs
CYT006-AngQb
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2007-005843-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005843-93.